Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Iberdomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: An update from the phase 2 EMN26 trial

View Full Paper
Ask AI
Bookmark
Share

Authors

EKEirini KatodrytouPGPaulus A.F. GeertsCMCecile Sonntag Mottier

Discussion

Loading...

Member takes

Overview

Phase 2 EMN26 trial shows improved response and safety of iberdomide maintenance after stem-cell transplantation in myeloma.

Key Points

  • Evaluate the efficacy and safety of iberdomide maintenance post-autologous stem-cell transplantation in multiple myeloma patients.
  • Conducted a phase 2 trial with cohorts receiving different doses of iberdomide after ASCT.
  • Included patients aged ≥18 years with newly diagnosed multiple myeloma achieving partial response post-induction therapy.
  • Evaluated primary and secondary outcomes, including response rates and minimal residual disease status.
  • Improvement in response within 6 months seen in multiple cohorts, with 78% achieving complete response at optimal dose.
  • Progression-free survival rates at 2 years were 92%, 82%, and 84% across the different doses.
  • Neutropenia was the most common adverse event, observed in 48-60% of patients.

Cite This Study

Katodrytou et al. (2025) studied this question.

synapsesocial.com/papers/693624d44fa91c937236cff0https://doi.org/10.1182/blood-2025-101
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Longitudinal analysis of MRD negativity and immune dynamics in patients with transplant-ineligible newly diagnosed multiple myeloma treated with iberdomide, daratumumab, and dexamethasone from the CC-220-MM-001 trial2025 · 1 citations
  2. 2Iberdomide plus daratumumab and dexamethasone (IberDd) in patients with newly diagnosed multiple myeloma by renal function: A subgroup analysis of the CC-220-MM-001 trial2025 · 2 citations
  3. 3Low conversion rates to minimal residual disease (MRD) negativity despite improved IMWG responses with lenalidomide-isatuximab maintenance after autologous stem cell transplant (ASCT) in multiple myeloma.2025
  4. 4Real-world efficacy and safety of ixazomib maintenance therapy in Chinese patients with newly diagnosed multiple myeloma: A multicenter retrospective study2025
  5. 5The Role of CELMoD Agents in Multiple Myeloma2025 · 4 citations